Floatz logo

89zr-dfo-n-suc-c9scfv

Lung Carcinoma

Var2 PharmaceuticalsradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

67 Active assets in the Lung Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Carboplatin
SystImmune Inc.
Phase 3B

View all 50 →

Same molecule, other indications

89zr-dfo-n-suc-c9scfv is also rated in:

colon carcinomaDormant
C
Indicative ·
39 / 100
View asset →
rectal carcinomaDormant
C
Indicative ·
39 / 100
View asset →
chondrosarcomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →